NRBO
Price
$3.10
Change
+$0.08 (+2.65%)
Updated
Apr 24, 6:59 PM EST
SRNE
Price
$0.31
Change
-$0.00 (-0.00%)
Updated
Feb 22, 6:59 PM EST
12 days until earnings call
Ad is loading...

Analysis and predictions NRBO vs SRNE

Header iconNRBO vs SRNE Comparison
Open Charts NRBO vs SRNEBanner chart's image
NeuroBo Pharmaceuticals
Price$3.10
Change+$0.08 (+2.65%)
Volume$27.19K
CapitalizationN/A
Sorrento Therapeutics
Price$0.31
Change-$0.00 (-0.00%)
Volume$77.42M
CapitalizationN/A
View a ticker or compare two or three
NRBO vs SRNE Comparison Chart

Loading...

NRBODaily Signal changed days agoGain/Loss if shorted
 
Show more...
SRNEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NRBO vs. SRNE commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRBO is a Hold and SRNE is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (NRBO: $3.02 vs. SRNE: $0.01)
Brand notoriety: NRBO and SRNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NRBO: 30% vs. SRNE: 26%
Market capitalization -- NRBO: $15.21M vs. SRNE: $11.03M
NRBO [@Biotechnology] is valued at $15.21M. SRNE’s [@Biotechnology] market capitalization is $11.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $567.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NRBO’s FA Score shows that 1 FA rating(s) are green whileSRNE’s FA Score has 1 green FA rating(s).

  • NRBO’s FA Score: 1 green, 4 red.
  • SRNE’s FA Score: 1 green, 4 red.
According to our system of comparison, SRNE is a better buy in the long-term than NRBO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NRBO’s TA Score shows that 3 TA indicator(s) are bullish while SRNE’s TA Score has 2 bullish TA indicator(s).

  • NRBO’s TA Score: 3 bullish, 4 bearish.
  • SRNE’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NRBO is a better buy in the short-term than SRNE.

Price Growth

NRBO (@Biotechnology) experienced а -11.18% price change this week, while SRNE (@Biotechnology) price change was -45.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.41%. For the same industry, the average monthly price growth was -3.09%, and the average quarterly price growth was +1263.37%.

Reported Earning Dates

NRBO is expected to report earnings on Mar 29, 2024.

SRNE is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Biotechnology (+0.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for NRBO with price predictions.
OPEN
A.I.dvisor published
a Summary for SRNE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NRBO($15.2M) has a higher market cap than SRNE($11M). NRBO YTD gains are higher at: -18.303 vs. SRNE (-87.854).
NRBOSRNENRBO / SRNE
Capitalization15.2M11M138%
EBITDAN/AN/A-
Gain YTD-18.303-87.85421%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
NRBO vs SRNE: Fundamental Ratings
NRBO
SRNE
OUTLOOK RATING
1..100
5128
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
8557
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a20

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRNE's Valuation (8) in the null industry is in the same range as NRBO (18). This means that SRNE’s stock grew similarly to NRBO’s over the last 12 months.

SRNE's Profit vs Risk Rating (100) in the null industry is in the same range as NRBO (100). This means that SRNE’s stock grew similarly to NRBO’s over the last 12 months.

NRBO's SMR Rating (98) in the null industry is in the same range as SRNE (100). This means that NRBO’s stock grew similarly to SRNE’s over the last 12 months.

SRNE's Price Growth Rating (57) in the null industry is in the same range as NRBO (85). This means that SRNE’s stock grew similarly to NRBO’s over the last 12 months.

SRNE's P/E Growth Rating (100) in the null industry is in the same range as NRBO (100). This means that SRNE’s stock grew similarly to NRBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NRBOSRNE
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
75%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NRBODaily Signal changed days agoGain/Loss if shorted
 
Show more...
SRNEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QTWO53.391.64
+3.17%
Q2 Holdings
FBMS25.210.60
+2.44%
First Bancshares
PHG21.010.40
+1.94%
Koninklijke Philips NV
STRR0.890.01
+1.66%
Star Equity Holdings
CTGO20.09-0.06
-0.30%
Contango ORE

NRBO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRBO has been loosely correlated with TCRT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NRBO jumps, then TCRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRBO
1D Price
Change %
NRBO100%
-3.21%
TCRT - NRBO
50%
Loosely correlated
+10.09%
ARGX - NRBO
45%
Loosely correlated
+1.72%
BLUE - NRBO
37%
Loosely correlated
+1.78%
SYRE - NRBO
37%
Loosely correlated
+2.87%
CMRA - NRBO
34%
Loosely correlated
N/A
More